Epygenix Therapeutics is a clinical stage biopharmaceutical company developing the precision medicine for rare and refractory genetic epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome.
Epygenix zebrafish-to-man translation strategy expedited the further investigation of EPX-100, -200, and -300 in Dravet syndrome patients.
Epygenix Therapeutics focuses on development of new treatments for rare and catastrophic forms of genetic epilepsy, including Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, Cute Syndrome, and Ohtahara Syndrome.
Our technology rapidly identifies antiepileptic drugs and monitors toxicology – Epygenix Therapeutics used an innovative zebrafish-based platform applying phenotype-based in vivo screening.
What is Epygenix?
Epygenix Therapeutics is a clinical stage biopharmaceutical company developing drugs to treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not sufficient, and the constant care required can severely impact the quality of life for the entire family.